Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
366 Leser
Artikel bewerten:
(0)

Novo Nordisk A/S: Ozempic (semaglutide) recommended for approval by the European regulatory authorities

Bagsværd, Denmark, 15 December 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes mellitus.

The CHMP recommends Ozempic, the intended brand name for once-weekly semaglutide, to be indicated as monotherapy when metformin no longer provides sufficient treatment or is contraindicated and as an addition to other medicinal products for the treatment of diabetes. The indication also refers to specific sections of the label for study results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied. The label furthermore reflects the superior reduction in body weight achieved with Ozempic relative to comparator treatments and the statistically significant reduction in diabetic nephropathy with Ozempic relative to standard of care.

As an integral part of the approval, Novo Nordisk has committed to conduct post-approval safety studies including a long-term diabetic retinopathy outcome study. Furthermore, as required for all long-acting GLP-1 products approved in the EU, Ozempic will be enrolled in the data collection for the registry of medullary thyroid carcinoma.

"We are very excited about the positive opinion for Ozempic for treatment of people with type 2 diabetes in Europe, many of whom are still looking for new and more efficacious solutions to better manage their disease," said Mads Krogsgaard Thomsen, executive vice president and chief science officer. "We believe Ozempic, with its unique clinical profile, has the potential to set a new standard for treatment of type 2 diabetes."

Novo Nordisk expects to receive final marketing authorisation from the European Commission in the first quarter of 2018.

About Ozempic
Ozempic (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The review of Ozempic is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some individuals with high cardiovascular risk profiles and people with and without renal disease.

Ozempic was recently approved by the US Food and Drug Administration and is currently under review by several regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency.

Further information

Media:
Katrine Sperling +45 4442 6718 krsp@novonordisk.com (mailto:krsp@novonordisk.com)
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com (mailto:mailtokiau@novonordisk.com)
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com (mailto:phak@novonordisk.com)
Hanna Ögren +45 3079 8519 haoe@novonordisk.com (mailto:haoe@novonordisk.com)
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com (mailto:armk@novonordisk.com)
Christina Kjær +45 3079 3009 cnje@novonordisk.com (mailto:cnje@novonordisk.com)
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com (mailto:kpvj@novonordisk.com)

Company announcement No 92 / 2017


PR171215_Ozempic_CHMP_opinion_UK (http://hugin.info/2013/R/2156392/828746.pdf)



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.